Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

April 27, 2023

https://www.globenewswire.com/news-release/2023/04/27/2656976/0/en/Tempest-to-Report-Early-Results-from-Global-Randomized-Phase-1b-2-Combination-Study-of-TPST-1120-in-First-Line-Hepatocellular-Carcinoma.html

BRISBANE, Calif., April 27, 2023 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq:TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced the company plans to report early data from its Phase 1b/2 combination study of TPST-1120 in first-line hepatocellular carcinoma in a premarket press release and webcast Friday, April 28, 2023.

Read more at globenewswire.com

Related news for (TPST)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.